Upperline Health

CEO Will W. Savage sets strategy, while clinical direction is led by Dr. Andrew Woods as Chief Medical Officer. The board includes representatives from private-equity investors General Atlantic, Frist Cressey Ventures, and Health Velocity Capital, who participate in capital allocation decisions.

The firm identifies independent podiatry, vascular surgery, and wound care practices seeking to transition to value-based care. It partners with physicians through practice acquisitions and joint ventures, using its centralized infrastructure to improve margins and outcomes while maintaining local brand identity.

Neither—Upperline is a healthcare operating company backed by institutional capital including General Atlantic, Frist Cressey Ventures, and Health Velocity Capital. It functions as a management services organization and physician practice aggregator, not a family office or venture fund.

Upperline makes growth-stage investments in existing physician practices (typically $1M–$10M per transaction) and greenfield ambulatory surgery centers. It does not seed startups but rather acquires established, revenue-generating clinics with ≥3 providers and ≥5 years of operating history.

Upperline has no disclosed avoidance list, but all of its disclosed activities focus on lower-extremity care. It does not operate in primary care, pediatrics, or general surgery beyond the foot and ankle.

General Atlantic led Upperline's $58M series B round in 2021 and holds a board seat. The private-equity firm typically retains minority stakes in growth healthcare platforms; it has invested across multiple provider aggregators including more than a dozen physician-practice roll-ups.

Upperline Health is not a family office—its capital comes from institutional investors: pension funds, endowments, and high-net-worth individuals that invest in General Atlantic, Frist Cressey Ventures, and Health Velocity Capital funds.